Skip to main content
    R

    Rigel Pharmaceuticals Inc (RIGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $43.73
    -0.73 (-1.64%)

    Market Cap: $837.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rigel Pharmaceuticals Inc (RIGL) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Rigel Pharmaceuticals (RIGL) trades at 14.2x trailing earnings and 2.8x sales. Its P/S of 2.8x is above its 5-year median of 2.1x. Its forward P/E is 9.3x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 52.7% higher over the next year.

    MultipleValue
    P/E (trailing)14.2x
    Forward P/E9.3x
    Price to sales2.8x
    Price to book1.8x
    EV/EBITDA9.8x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 30.0% below 4.0x.

    MultipleCurrent5-year median10-year median
    P/S2.8x2.1x4.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 3 of the 10 year ends shown that have a P/E, its P/E ranged from 6.6x in 2025 to 378.6x in 2021.

    Year endPriceP/EP/SP/B
    2025$42.836.6x2.6x2.1x
    2024$16.8217.9x1.7x92.0x
    2023$14.50N/A2.2xN/A
    2022$15.00N/A2.2xN/A
    2021$26.50378.6x3.0x14.9x
    2020$35.00N/A10.1x17.4x
    2019$21.40N/A6.0x6.7x
    2018$23.00N/A8.6x3.5x
    2017$38.80N/A61.0x5.6x
    2016$23.80N/A10.9x4.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RIGL

    What is RIGL's forward P/E ratio?

    Rigel Pharmaceuticals has a forward P/E ratio of 9.3x.

    Is RIGL stock overvalued?

    GNG's valuation label for RIGL is Fairly valued.

    What is RIGL's price to sales ratio?

    Rigel Pharmaceuticals has a price to sales ratio of 2.8x.